SIP 1.55% $1.31 sigma pharmaceuticals limited

forgotten turnaround

  1. 2,378 Posts.
    lightbulb Created with Sketch. 656
    think it was efficacy issues a few years ago undermined SIP since then they have it appears turned the business into a player with improved margins , capacity and distribution the directors who seem to be madly buying up additional stock to add to their already significant holdings also appear to have met performance benchmarks, combined with the grinding share buy back and sideways SP it might be due for an upgrade around March with the release of finacials, while commodities look excuiting the possibility of a retreat is not at all exciting so SIP looks to me like a possibility with a probability of a return improving the sp. and the divvy
 
watchlist Created with Sketch. Add SIP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.